D.C. Circuit Court Upholds Legality of Generic Drugmakers Omitting Patented Uses from Labels

The U.S. Court of Appeals for the D.C. Circuit has upheld the legality of the so-called “skinny label” or “carve-out” practice, a regulatory pathway that allows generic drug manufacturers to exclude certain patented uses from their product labeling. The decision reaffirms the ability of generic drugmakers to market their products for non-patented indications while avoiding infringement on brand-name drug patents covering other uses. This ruling is seen as a significant development in ongoing disputes between brand-name pharmaceutical companies and generic manufacturers over intellectual property rights and competition.

The case centered on whether generic drugmakers could legally omit specific patented indications from their labeling under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The court’s decision confirms that this practice remains permissible, provided it complies with FDA regulations and does not mislead consumers or healthcare providers about the approved uses of the medication. The ruling comes amid broader debates over balancing innovation incentives for brand-name drugs with efforts to increase access to lower-cost generics. Legal experts note that this decision may have implications for future patent litigation in the pharmaceutical industry, as well as for FDA policy regarding labeling requirements.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 6, 2025

Author

Mark Chiang